Liver Diseases  >>  tivantinib (ARQ 197)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
NCT02029157: A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

Checkmark Final results from P3 JET-HCC trial in HCC
Mar 2017 - Mar 2017: Final results from P3 JET-HCC trial in HCC
Checkmark JET-HCC trial in HCC
Mar 2017 - Mar 2017: JET-HCC trial in HCC
Completed
3
386
Japan
ARQ197, Placebo
Kyowa Kirin Co., Ltd.
Liver Cancer
08/17
08/17

Download Options